SEC Tracker
Get the app
OGN · XBRL financial data

Organon financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (OGN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue1,598*1,6221,6071,5821,592*1,5131,5941,6021,507*1,4601,5581,574
Cost of goods and services sold683*665668659696*672720745766*677711705
Gross profit915*957939923896*841874857741*783847869
Selling, general and administrative469*431437422470*420453415433*424434421
Interest expense129*131131126132*124131128121*111108106
Income tax expense (benefit)(442)*3540(152)20*14848357*677591
Net income (loss)546*201195359109*87145160(205)*146108164
Earnings per share, basic USD per share2.14*0.780.761.390.42*0.340.560.61(0.79)*0.560.410.62
Earnings per share, diluted USD per share2.13*0.780.751.380.42*0.330.560.61(0.78)*0.550.400.60
Weighted average shares, basic millions of shares256*256257257258*258260260260*260263263
Weighted average shares, diluted millions of shares257*258259260260*261260261261*263270272

Balance sheet

CSV

Fiscal quarters (OGN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents6935757047636755475996725741,1161,1321,455
Accounts receivable1,7441,5471,6171,6851,3581,4571,4841,4841,3311,3841,4921,480
Inventory1,3151,2631,2871,3831,3211,3621,4541,4881,4061,3731,3511,355
Total current assets4,5084,1964,5094,7564,3484,3714,6184,7004,3524,9325,1115,369
Property and equipment, net1,1831,1801,1621,2041,1681,1971,2661,2901,3031,2791,2811,286
Right-of-use asset173———157———155———
Goodwill4,6034,6034,6034,6034,6804,6804,6804,6804,1534,1534,1534,153
Total assets12,05811,89112,15412,75213,10113,15613,50013,55212,86712,99613,17813,401
Accounts payable1,3149551,2431,0921,1531,0061,0671,0749529831,051982
Current portion of long-term debt999102020——————
Total current liabilities2,9182,5452,7552,7902,7182,6152,7962,6792,3902,5002,6162,652
Long-term debt8,7518,7058,6478,7398,8608,9368,7818,7838,6288,5538,4798,485
Lease liability, non-current125———112———116———
Total liabilities12,12811,84312,01012,25912,62912,61412,76712,64612,11512,09312,17212,208
Retained earnings4435736909751,0101,0261,1631,3181,1091,2531,3521,511
Total stockholders' equity(70)481444934725427339067529031,0061,193
Total liabilities and equity12,05811,89112,15412,75213,10113,15613,50013,55212,86712,99613,17813,401
Common shares outstanding (cover page) millions of shares256257257258258260260260260263263263

Cash flows

CSV

Fiscal quarters (OGN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)546*201195359109*87145160(205)*146108164
Stock-based compensation27*2628*25*26*2422*24*7*1925*21*
Net cash from operating activities397*76332*141*390*75220*264*141*225107*370*
Purchases of property and equipment79*4632*42*55*3239*46*45*3742*44*
Net cash from investing activities(81)*(96)(46)*(75)*(296)*(172)(38)*(115)*(65)*386(76)*(44)*
Dividends paid73*7079*74*74*7110*3*4*56*5*
Proceeds from long-term debt0*01,036*0*150*90340*300*325*00*0*
Repayments of long-term debt2*21,041*2*152*93541*372*507*320*0*
Net cash from financing activities(77)*(74)(134)*(78)*(82)*(75)(223)*(76)*(187)*(38)(12)*(5)*
Net change in cash279*(118)129*59*(88)*(128)52*73*(98)*54216*323*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Organon1,4551,574370*262.6M— 10-QSep 30, 2026
Cytokinetics20348(124)*139.3M7.7 quarters 10-QSep 30, 2026
TG Therapeutics48324039*153.1M— 10-QJun 30, 2026
Catalyst Pharmaceuticals75614960122.4M— 10-QMar 31, 2026
Summit Therapeutics151not reported(160)*799.8M4.5 quarters 10-QSep 30, 2026
Xenon Pharmaceuticals120not reported(95)*96.8M9.8 quarters 10-QJun 30, 2026
Twist Bioscience117not reported1.1*62.7M— 10-QJun 30, 2026
Acadia Pharmaceuticals32234212*172.8M— 10-QSep 30, 2026
Protagonist Therapeutics420213219*64.7M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.